lidocaine has been researched along with Cervical Dystonia in 2 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Cervical Dystonia: A common form of DYSTONIA due to involuntary sustained or spasmodic, repetitive muscle contractions in the neck region. According to the position of the twisted neck and head, cervical dystonia can be categorized as torticollis, laterocollis, retrocollis, and a combination of these abnormal postures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the clinical efficacy of mexiletine, a derivative oral form of lidocaine, for treatment of spasmodic torticollis." | 9.08 | Mexiletine in the treatment of spasmodic torticollis. ( Hayashi, R; Miki, J; Momoi, H; Ohara, S; Yanagisawa, N, 1998) |
| "We studied the clinical efficacy of mexiletine, a derivative oral form of lidocaine, for treatment of spasmodic torticollis." | 5.08 | Mexiletine in the treatment of spasmodic torticollis. ( Hayashi, R; Miki, J; Momoi, H; Ohara, S; Yanagisawa, N, 1998) |
| " This case report documents the first death associated with a Botox-lidocaine mixture given to a woman for chronic neck and back pain." | 3.73 | Fatal case of BOTOX-related anaphylaxis? ( Goldberger, BA; Hopkins, C; Li, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Goldberger, BA | 1 |
| Hopkins, C | 1 |
| Ohara, S | 1 |
| Hayashi, R | 1 |
| Momoi, H | 1 |
| Miki, J | 1 |
| Yanagisawa, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury[NCT02736890] | Phase 2 | 8 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to funding not available to continue) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Mean change from baseline. Participants are asked Taking into account your pain level and how it affects your life, are you feeling better, the same or worse than when you started treatment? and then to quantify the magnitude of the change. with the 7-Point guy Farrar which measures the global treatment effect from with scale from 0 to 6, higher score indicates worse outcomes." (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 2.2 | 2.4 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo Then Botulinum Toxin A | 0.3 | 0.3 | 0 | 0 | 5 | 5 | 3 | 1 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting day-to-day activities subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4.2 | 5.4 | 5 | 5 | 4.8 | 7 | 6.7 | 7 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.3 | 2.7 | 2.7 | 2.7 | 2.7 | 2 | 3 | 4 | 5 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting mood subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.6 | 6.6 | 5.8 | 5.2 | 5.6 | 7 | 7 | 7.3 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.7 | 2.7 | 2.7 | 4.3 | 5.7 | 2 | 3 | 4 | 7 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting sleep subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.8 | 4.6 | 5 | 6 | 6.2 | 8 | 8 | 8 | 7.3 |
| Placebo Then Botulinum Toxin A | 6.7 | 4.7 | 3.3 | 6 | 6.7 | 1 | 3 | 4 | 5 |
Participant rated pain intensity from 0-10, with higher score indicating more pain (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 7.6 | 6.4 | 5.6 | 5.6 | 5.6 | 8 | 8 | 6.7 | 8 |
| Placebo Then Botulinum Toxin A | 8 | 8 | 8 | 8 | 8 | 5 | 5 | 6 | 7 |
PGI measures activity affected by pain. Full score is 0 to 10000, with higher score indicating better function (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4250 | 5240 | 5219 | 3725 | 4330 | 3333.3 | 3333.3 | 3333.3 | 3333.3 |
| Placebo Then Botulinum Toxin A | 1500 | 1550 | 1825 | 2800 | 1800 | 3500 | 3750 | 3000 | 1500 |
1 trial available for lidocaine and Cervical Dystonia
| Article | Year |
|---|---|
Mexiletine in the treatment of spasmodic torticollis.
Topics: Administration, Oral; Adult; Analysis of Variance; Anesthetics, Local; Dystonia; Electromyography; F | 1998 |
1 other study available for lidocaine and Cervical Dystonia
| Article | Year |
|---|---|
Fatal case of BOTOX-related anaphylaxis?
Topics: Adult; Anaphylaxis; Anesthetics, Local; Botulinum Toxins, Type A; Fatal Outcome; Female; Humans; Lid | 2005 |